All In Biotech

Drug Trial Radar · NCT07650942

Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Re-randomized Study To Assess the Efficacy and Safety With Hemay005 Tablets in Chinese Patients With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

May 2028

Study completion Feb 2029

Sponsor

Sponsor type
Industry
First posted
Jun 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with moderately to severely active ulcerative colitis.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • Hemay005 tabletDrug

    Participants receive treatment with Hemay005 tablet during the Induction Phase (week I-0\~I-12).

  • PlaceboDrug

    Participants receive treatment with placebo tablet during the Induction Phase (week I-0\~I-12).

  • Hemay005 tabletDrug

    Participants receive treatment with Hemay005 tablet during the Maintenance Phase (week M-0\~M-40).

  • PlaceboDrug

    Participants receive treatment with placebo during the Maintenance Phase (week M-0\~M-40).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Induction Phase: Percentage of Participants With Clinical Remission at Week 12.Time frame: Induction Phase Week 12
  2. Maintenance Phase: Percentage of Participants With Clinical Remission at Week 40.Time frame: Maintenance Phase: Week 40

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital,Sun Yat-Sen University

    Guangzhou, China

  • The Sixth Affiliated Hospital,Sun Yat-Sen University

    Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.